BCIQ Profiles

Company Profile Report

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy
Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The Roivant Sciences GmbH subsidiary will receive $60 million up front and up to $53 million in milestones, plus

Read the full 526 word article

How to gain access

Continue reading with a
two-week free trial.